Activity ID



April 4, 2023

Format Type


CME Credit




CME Provider: Potomac Center for Medical Education

Description of CME Course

With the number of Alzheimer’s disease (AD) specialists limited in many parts of the country, many primary care physicians (PCPs) must provide care, often beyond their level of training or expertise, for patients with AD or early signs of AD. Too often early signs and symptoms of AD are missed or not given appropriate priority, and thus specialty referrals occur later in the course of disease. Furthermore, the difficulty in diagnosing AD and the lack of any disease modifying therapy (DMT) for AD has fostered clinical inertia among many physicians. However, the approval of the first blood test for AD in November 2020 and the first DMT, aducanumab, in June 2021, should begin to provide the armamentarium that has been missing from AD management since it was first characterized.

Given that 85% of initial AD diagnoses are made by non-specialists, yet almost 40% of PCPs are not comfortable making the diagnosis and 50% do not consider medical professionals prepared to care for people with AD, it is vital that PCPs receive education to help them stay abreast of these recent developments, be able to integrate them into practice where appropriate and in an evidence-based manner, and be aware of emerging developments in AD diagnosis and

The educational program, “A NEW DAWN IN ALZHEIMER’S DISEASE MANAGEMENT: Recent Advances in Diagnosis and Treatment” will provide the latest AD clinical developments in a manner that is most relevant to the primary care setting and will provide access to AD resources and experts to help prepare them for the potential sea change in AD management.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Educational Objectives

-Integrate validated assessment tools and discuss available biomarker testing to diagnose Alzheimer’s disease early in the course of disease
-Make timely and appropriate referrals to AD specialists for patients with symptoms of AD or other dementias
-Assess the safety and efficacy profiles of current and emerging treatment options for Alzheimer’s disease


Alzheimer's Disease, Disease Modifying Therapy, Neurology Referral


Interpersonal & Communication Skills, Medical Knowledge, Patient Care & Procedural Skills, Practice-based Learning & Improvement

CME Credit Type

AMA PRA Category 1 Credit

Practice Setting

Inpatient, Outpatient, Rural, Urban

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.